Adding Pembrolizumab To Preoperative Radiotherapy and Surgery Improves DFS for Patients with Stage III Soft Tissue Sarcomas of the Extremity By Ogkologos - December 2, 2024 737 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from the SU2C-SARC032 study Source RELATED ARTICLESMORE FROM AUTHOR The Legacy of the ESMO Patient Engagement Summit 2025: Advancing Rights of Patients with Cancer via Cross-Border Best Practices and Collaboration Sustained PFS Benefit of Imlunestrant Over SoC in Patients with ESR1-mutated Advanced Breast Cancer ESMO Welcomes Launch of Health Package Introducing EU Measures That Can Boost Innovation in Oncology and Help Prevent New Cancer Cases MOST POPULAR Looking to Help Rebuild Strength After Breast Cancer Treatment? Soccer May... April 26, 2021 For Early-Stage Lung Cancer, Nivolumab and Chemo before Surgery Proves Effective May 20, 2022 Hospital Lockdown Prevents Breast Cancer Patient from Receiving Treatment for 3... May 17, 2021 Grieving for Your Old Life After Cancer September 10, 2020 Load more HOT NEWS FDA Approves Pembrolizumab with Enfortumab Vedotin-ejfv for Muscle Invasive Bladder Cancer Ponatinib Effectively Treats Newly Diagnosed Acute Lymphoblastic Leukemia: The ASCO Plenary... Cómo los ensayos clínicos pueden llevar a un tratamiento que salve... Maintenance Regorafenib Significantly Delays Disease Progression After First-Line Treatment in Patients...
